鼻咽癌
医学
肿瘤科
内科学
放射治疗
癌
血管内皮生长因子受体
免疫系统
免疫疗法
癌症
癌症研究
免疫学
作者
Xian Chen,Yong Li,Xin Qu,Yongsong Ye,Xuemin Du,Rui Zhou,Yanchun Qu,Yuandong Zhu,Haibo Zhang
标识
DOI:10.1166/jbn.2023.3550
摘要
Nasopharyngeal carcinoma has a good prognosis with intensity-modulated radiotherapy (IMRT) but recurrence occurs in 8–10% of patients, mostly in the form of distant metastases. Current systemic treatments for relapsed/metastatic (R/M) nasopharyngeal carcinoma are limited, resulting in poor overall survival rates. Immune checkpoint inhibitors have shown some activity, but their small sample size and lack of overall survival data limit their effectiveness. This study reports a patient with R/M nasopharyngeal carcinoma who had a durable response to salvage therapy with camrelizumab plus anlotinib, with no serious side effects and high quality of life. The combination of immune checkpoint inhibitors and antivascular monoclonal antibodies may have a mechanism for enhancing the antitumor response. VEGF/VEGFR2 inhibitors combined with PD-1 inhibitors are being clinically explored as a potential new treatment option for R/M nasopharyngeal carcinoma. These findings offer hope for the development of effective, tumor-specific treatments for patients with R/M nasopharyngeal carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI